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BRCA1 plays an important role in mechanisms of response to double-strand breaks, participating in genome
surveillance, DNA repair, and cell cycle checkpoint arrests. Here, we identify a constitutive BRCA1–c-Abl complex
and provide evidence for a direct interaction between the PXXP motif in the C terminus of BRCA1 and the SH3
domain of c-Abl. Following exposure to ionizing radiation (IR), the BRCA1–c-Abl complex is disrupted in an
ATM-dependent manner, which correlates temporally with ATM-dependent phosphorylation of BRCA1 and ATM-
dependent enhancement of the tyrosine kinase activity of c-Abl. The BRCA1–c-Abl interaction is affected by
radiation-induced modification to both BRCA1 and c-Abl. We show that the C terminus of BRCA1 is phosphory-
lated by c-Abl in vitro. In vivo, BRCA1 is phosphorylated at tyrosine residues in an ATM-dependent, radiation-
dependent manner. Tyrosine phosphorylation of BRCA1, however, is not required for the disruption of the BRCA1–
c-Abl complex. BRCA1-mutated cells exhibit constitutively high c-Abl kinase activity that is not further increased on
exposure to IR. We suggest a model in which BRCA1 acts in concert with ATM to regulate c-Abl tyrosine kinase
activity.
Germ line mutations in BRCA1 are responsible for the majority
of hereditary breast cancers and cause almost all the familial cases
involving both breast and ovarian cancers (15). The patients are
heterozygous, and loss of heterozygosity is observed in the pri-
mary breast and ovarian tumors, providing clues that the BRCA1
protein is encoded by a tumor suppressor gene which functions as
a genome caretaker (25). However, although there is now a pleth-
ora of data suggesting that BRCA1 is involved in DNA repair, the
biological role of BRCA1 remains unclear (14, 50).
BRCA1 is a nuclear phosphoprotein with an N-terminal zinc
ring finger domain which mediates protein-protein interactions
(6) and a C-terminal tandem BRCT domain (47). BRCT motifs
are encountered in several DNA repair and cell cycle control
proteins (7, 47). Treatment with ionizing radiation (IR) or other
DNA-damaging agents triggers phosphorylation of BRCA1 and
its cellular relocalization as discrete nuclear dots (33). BRCA1
interacts with RAD51, a human homolog of RecA (34), and with
the hRAD50-hMRE11-NBS complex (52). The homologous
complex in Saccharomyces cerevisiae, Rad50-Mre11-Xrs2, has
been reported to be required for nonhomologous end joining,
homologous recombination, and telomere maintenance (5). The
ATM and ATR kinases, both implicated in responses to geno-
toxic stress, are also required for the radiation-induced phosphor-
ylation of BRCA1 (12, 38). More recently, a group of complexed
BRCA1 protein partners forming the BRCA1-associated genome
surveillance complex (BASC) has been identified; all the BASC
components are involved in DNA damage recognition and/or
DNA replication-associated repair (45). Lastly, BRCA1 was also
shown to be associated with Fanconi anemia protein D2 (16) and
BACH1 helicase (8).
ATM and RAD51, two of the protein partners of BRCA1,
are also complexed with the nonreceptor tyrosine kinase c-Abl
(35, 49). c-Abl is the cellular homolog of the Abelson murine
leukemia virus oncogene, v-Abl, which encodes a ubiquitously
expressed protein (36). Homozygous null mutation of c-Abl
confers neonatal lethality in mutant mice despite normal fetal
development (40). Although no human genetic disease has yet
been specifically associated with mutations in c-Abl, c-Abl is
activated as an oncogene through its fusion with BCR in
chronic myelogenous leukemia (13, 36, 37, 44). The c-Abl
protein has a number of specific domains, notably Src homolog
binding sites (SH domains), including a tyrosine kinase do-
main, SH2 (which has a high affinity for phosphorylated ty-
rosine residues), and SH3 (which preferentially binds to pro-
line-rich domains) (2, 28, 29, 36, 48). The c-Abl tyrosine kinase
is activated in response to radiation through an ATM-depen-
dent pathway (4, 35).
Here, our findings show that BRCA1 and c-Abl interact
constitutively. Following exposure to IR, the complex is dis-
rupted in an ATM-dependent manner, which correlates tem-
porally with the phosphorylation of BRCA1 and the increase
of the tyrosine kinase activity of c-Abl. Loss of BRCA1 results
in constitutively elevated c-Abl tyrosine kinase activity. Our
findings suggest that one function of BRCA1 is to control c-Abl
activity in an ATM-dependent manner.
MATERIALS AND METHODS
Cell culture. The 293 cell line is an immortalized line derived from a primary
human embryonal kidney line transformed by human adenovirus 5. The
* Corresponding author. Mailing address: Genome Damage and
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HCC1937 (BRCA1-mutated) tumor cell line is derived from a human ductal
carcinoma bearing a BRCA1 5382insC mutation in one allele and a deletion of
the second allele. The BRCA1 protein in HCC1937 lacks the BRCA1 C termi-
nus, and extracts show very low levels of BRCA1 protein (9, 39). AT5BIVA
(ATM/) and MRC5VI (control) are simian virus 40-transformed human fi-
broblasts. The cells were cultured in Dulbecco’s modified Eagle’s medium sup-
plemented with antibiotics and 20% fetal calf serum.
Recombinant adenoviruses and viral infection. The construction of the ad-
enoviruses and the infection procedures have been described previously (31).
Briefly, AdBRCA1 and AdCo1 are nonreplicative E1/E3-defective recombinant
adenoviruses carrying a wild-type BRCA1 cDNA or an empty cassette, respec-
tively. The Ad1025 mutational change arose spontaneously and results in expres-
sion of the first 1,321 residues of BRCA1 but loss of the C terminus. The optimal
multiplicity of infection was determined after infection with control viruses
carrying the Escherichia coli LacZ transgene by scoring LacZ-positive blue cells.
GST fusion protein constructs. The pGST-BRCA1#1 to -#6 plasmids were
constructed from human BRCA1 cDNA. The GST-BRCA1#1 to -#6 fusion pro-
teins contain residues 1 to 324, 260 to 553, 502 to 802, 758 to 1064, 1005 to 1313, and
1314 to 1863 of BRCA1, respectively (34). The PXXP motif from residue 1856 in the
GST-BRCA1#6 constructs has been mutated by separately replacing prolines with
glycines using the primers 5-CTGGACACCTACCTGATTGCGCAGATCCCC
C-3 for #6-P1856G and 5-CCTGATACCCCAGATCGCGCACAGCCACTAC
C-3 for #6-P1859G with the QuickChange site-directed mutagenesis kit (Strat-
agene, La Jolla, Calif.). The mutated constructs were less stably expressed in E. coli
than the wild-type constructs, and a 20-fold-greater volume of bacteria was needed
to get similar protein levels. The pGST-BRCT tandem plasmid contains a portion of
BRCA1 encoding residues 1640 to 1863. All the pGST-cAbl plasmids were con-
structed from mouse c-Abl type IV cDNA. The SH domains of murine c-Abl type
IV are 99% identical to those of human c-Abl (36). The pGST-NSH, pGST-
SH3SH2kinase, and pGST-SH3 plasmids encode glutathione S-transferase
(GST) fusions to c-Abl residues 489 to 543, 15 to 607, and 15 to 138, respectively.
The GST-SH3 plasmid was constructed by insertion of a BamHI-HincII fragment of
the pGST-SH3SH2kinase plasmid into a BamHI-SmaI fragment of pGEX-4T-1
vector (Pharmacia, Bucks, United Kingdom). The GST-CTD fusion protein express-
ing the C-terminal domain of PolII, which is a substrate for c-Abl kinase (3), was
kindly provided by M. Bensaude (Ecole Normale Supérieure, Paris, France).
Irradiation. Irradiations were performed on ice using a -ray 137Cs source (20
Gy at 4 Gy · min1). Postirradiation incubations were carried out at 37°C.
Use of EA. Methyl 2,5-dihydroxycinnamate (erbstatin analog [EA]) (Calbio-
chem, Darmstadt, Germany) is about four times more stable than erbstatin in
calf serum (41). Cells treated with EA were incubated in Dulbecco’s modified
Eagle’s medium supplemented with antibiotics, 20% fetal calf serum, and 0.15 g
of EA · ml1 4 h before irradiation and renewed every hour up to the end of the
repair period.
Nuclear extracts. Nuclear extracts were prepared using a standard protocol
with minor modifications (30). Briefly, cells were collected by scraping and rinsed
by centrifugation with cold phosphate-buffered saline (1,500 rpm; 200  g; 4°C;
5 min). The pellet was suspended in hypotonic buffer (10 mM HEPES [pH 7.9],
10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol [DTT], 1 mM
phenylmethylsulfonyl fluoride) supplemented with 50 mM NaF, 2 mM sodium
orthovanadate, and protease inhibitors (Calbiochem) for 10 min at 4°C. Nuclei
were collected by centrifugation (4,000 rpm; 800  g; 4°C; 10 min) and resus-
pended in hypertonic buffer (20 mM HEPES [pH 7.9], 0.4 M NaCl, 1 mM
EDTA, 1 mM EGTA, 1 mM DTT, 1 mM phenylmethylsulfonyl fluoride, 10%
glycerol) supplemented with 0.6% NP-40, 50 mM NaF, 2 mM sodium orthovana-
date, and protease inhibitors. After being stirred for 15 min at 4°C, the super-
natant was collected by centrifugation (10,000 rpm; 1,500  g; 4°C; 5 min).
Aliquots were kept at 70°C. Protein concentrations were estimated using the
Bradford assay (Bio-Rad, Hercules, Calif.). Treatment of nuclear extracts with
-phosphatase (Pharmacia) was performed at 37°C for 20 min as recommended
by the manufacturer.
Immunoprecipitation and immunoblotting. For immunoprecipitation, im-
mune complexes were first precleared by stirring nuclear extracts, protein A-
Sepharose beads (Pharmacia), and preimmune immunoglobulin G (IgG) for 30
min at 4°C in NET-N buffer (50 mM Tris [pH 8], 1 mM EDTA, 120 mM NaCl,
0.5% NP-40) supplemented with phosphatase and protease inhibitors (see
above). After centrifugation, immunoprecipitation was performed with fresh
protein A-Sepharose beads, 300 g of precleared lysates, and 0.5 to 1 g of
specific monoclonal antibody for 4 h at 4°C. After four washes in NET-N,
immunoprecipitates were collected by centrifugation and kept in loading buffer
before being separated by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) (see below). Preimmune rabbit (DAKO, Glostrup, Den-
mark) and mouse (Jackson Immunoresearch, West Grove, Pa.) IgGs were used
as controls.
For immunoblotting, 100 g of cell extracts (unless otherwise stated) was
boiled in loading buffer and separated by SDS-PAGE. The protein transfer to
nitrocellulose membrane (Schleicher and Schuell, Dassel, Germany) was per-
formed for 4 h with a semidry transfer system (Bio-Rad), and the membrane was
blocked overnight in 5% milk TBS-T solution (100 mM Tris [pH 8], 150 mM
NaCl, 1% Tween 20) supplemented with 0.1% sodium azide. Primary antibody
was applied for 6 h in 2% milk TBS-T solution. Anti-BRCA1 and anti-c-Abl
antibodies were from Oncogene Research (Darmstadt, Germany). Anti-p-Tyr
(Y-99) antibody was from Santa Cruz Biotechnology (Santa Cruz, Calif.). After
the membrane was washed for 1 h in TBS-T, anti-rabbit (DAKO) or anti-mouse
(Jackson Immunoresearch) secondary antibody was applied in 2% milk TBS-T
solution for 40 min, and the membrane was rewashed against TBS-T for 1 h.
Blotting was revealed using an ECL kit (Amersham, Little Chalfont, United
Kingdom).
GST fusion protein pull-down assay. Synthesis of GST fusion proteins was
performed as previously described, and protein loading was estimated following
electrophoresis and Coomassie blue staining (22). Briefly, bacterial lysates were
incubated in GST-Sepharose beads (Pharmacia). After being washed, purified
GST fusion proteins (5 to 10 g) were incubated in nuclear extracts of 293 cells
(100 g) and in NET-N buffer for 1 h at 4°C. GST-bound protein complexes were
washed and separated by SDS-PAGE. To examine a direct interaction, the GST
fusion proteins were eluted with glutathione as recommended by the manufac-
turers. The presence of the GST fusion protein was examined by using the
anti-GST antibody provided by Pharmacia.
c-Abl tyrosine kinase activity assay. One hundred micrograms of lysates was
subjected to immunoprecipitation with anti-c-Abl antibody (Ab-3) (Oncogene
Research) for 2 h at 4°C. Kinase assays were performed by incubating the
immunoprecipitates with 2 Ci of [-32P]ATP and 20 M substrate peptide
EAIYAAPFAKKK (New England Biolabs, Beverly, Mass.) in c-Abl kinase
buffer (50 mM Tris [pH 7.5], 10 mM MnCl2, 1 mM DTT) for 20 min at 30°C (23).
Protein A-Sepharose beads bound to 32P-labeled substrates were collected, and
32P activity was quantified by liquid scintillation counting. In all these experi-
ments, the assay was verified by using purified c-Abl protein expressing only the
SH2 kinase domain or by immunoprecipitation with the anti-c-Abl (Ab-1; On-
cogene Research) antibody that inhibits kinase activity.
RESULTS
BRCA1 and c-Abl interact constitutively. The BRCA1–c-
Abl complex was identified by coimmunoprecipitation in nu-
clear extracts from the BRCA1- and c-Abl-positive cell line
293. Using two anti-BRCA1 antibodies with N-terminal and
C-terminal epitopes and two anti-c-Abl antibodies with kinase-
adjacent and C-terminal epitopes (Fig. 1A), the presence of
c-Abl protein was detected in immunoprecipitated BRCA1
and vice versa (Fig. 1B). HCC1937 (BRCA1-mutated) cells
show low levels of mutated BRCA1 but normal levels of c-Abl
(Fig. 1C). In these cells, no coimmunoprecipitation was ob-
served, most likely due to the low levels of BRCA1. This
demonstrates that coimmunoprecipitation depends upon the
presence of BRCA1 and is not due to nonspecific binding of
the antibodies (Fig. 1C). Additionally, in column chromatog-
raphy, BRCA1 and c-Abl coeluted in the 0.5 M KCl residual
fraction, consistent with an association between the two pro-
teins (data not shown).
c-Abl binds to the C-terminal domain of BRCA1. To identify
the region of BRCA1 that mediates the interaction with c-Abl,
the abilities of GST-tagged deletion constructs of BRCA1 to
bind endogenous c-Abl were examined. Synthesis of the GST-
BRCA1 fusion proteins was verified using a Coomassie blue-
stained SDS-PAGE gel, and the size of each product was as
anticipated (Fig. 2A and B). The GST-BRCA1#3 fusion pro-
tein was not stably expressed, as found previously (34). Fol-
lowing mixing of the GST-BRCA1 fusion proteins with nuclear
VOL. 22, 2002 BRCA1–c-Abl ASSOCIATION 4021
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extracts from 293 cells, c-Abl protein was detected among
proteins interacting with the GST-BRCA1#6 fusion product,
suggesting that c-Abl binds specifically to the C-terminal re-
gion of BRCA1 (residues 1314 to 1863) (Fig. 2B). The amount
of c-Abl protein bound to the BRCT tandem repeat is signif-
icantly reduced relative to the BRCA1#6 fusion construct
(Fig. 2B), suggesting that sequences adjacent to the BRCT
motifs are required for efficient interaction.
BRCA1 binds to the N-terminal domain of c-Abl. The abil-
ities of GST-tagged deletion contructs of c-Abl to bind BRCA1
were investigated to identify the region of c-Abl that mediates
interaction with BRCA1. Synthesis of the GST–c-Abl fusion
proteins was verified using a Coomassie blue-stained SDS-
PAGE gel, and the size of each product was as anticipated
(Fig. 2C and D). The GST–c-Abl fusion proteins were incu-
bated with nuclear extracts from 293 cells, and the adsorbates
were subjected to BRCA1 immunoblotting. BRCA1 was de-
tected among proteins bound to the SH3 domain and to a
fragment encompassing the SH2, SH3, and kinase domains
(Fig. 2C and D).
Mutation of the PXXP site in the BRCA1 C terminus abro-
gates the BRCA1–c-Abl interaction. The SH3 domain of c-Abl
has a high affinity for proline-rich PXXP sites (28, 36), and
significantly, the C terminus of BRCA1 encompasses such a
motif at residue 1853. To address whether the PXXP site is
essential for the BRCA1–c-Abl interaction, we replaced the
first or second proline in this motif in the GST-BRCA1#6
construct with a glycine, producing GST-BRCA1#6-P1856G
and -P1859G, respectively. Following mixing of the wild-type
or mutant GST-BRCA1#6 fusion protein with nuclear extracts
from 293 cells, c-Abl protein was not detected among proteins
interacting with either P1856G or P1859G, in contrast to the
results obtained with the wild-type fusion protein (Fig. 2E).
These findings show that the PXXP site in the C terminus of
BRCA1 is essential for the c-Abl–BRCA1 interaction involv-
ing the SH3 motif. To investigate whether this represents a
direct interaction, we mixed the eluted GST-SH3 fusion pro-
tein with either the wild-type or the mutated GST-BRCA1#6
protein. GST-SH3 was present only in the BRCA1 immuno-
precipitates using the GST-BRCA1#6 but not the PXXP-mu-
tated form, providing strong evidence that the SH3 domain of
c-Abl interacts directly with the PXXP domain in the C ter-
minus of BRCA1 (Fig. 2F).
The BRCA1–c-Abl complex is disrupted after irradiation.
IR induces ATM-dependent BRCA1 phosphorylation (12).
From immunoblotting performed with nuclear extracts from
irradiated 293 cells, partial phosphorylation of BRCA1 was
observed 1 h after irradiation with 20 Gy, and a large shift,
representing further phosphorylation event(s), was observed
after 4 h (Fig. 3A). The BRCA1 phosphorylation was progres-
sively lost after 8 h, returning to basal levels at 24 h (data not
shown). These shifts represent phosphorylation events, since
FIG. 1. Coimmunoprecipitation of BRCA1 and c-Abl. (A) Positions of the epitope domains of the anti-BRCA1 and the anti-c-Abl antibodies
used in this study. The MS110 and SG11 antibodies recognize the N-terminal and the C-terminal domain of BRCA1, respectively; the Ab-1 and
Ab-3 antibodies recognize the kinase-adjacent domain and the C-terminal domain of c-Abl, respectively. (B) Nuclear extracts from exponentially
growing 293 cells were subjected to BRCA1 and c-Abl immunoprecipitation (IP). The immunoprecipitates were analyzed by immunoblotting (IB).
The masses of endogenous BRCA1 and c-Abl are 220 and 140 kDa, respectively. BRCA1, anti-BRCA1 antibody; c-Abl, anti-c-Abl antibody.
(C) Nuclear extracts from exponentially growing HCC1937 cells were subjected to BRCA1 and c-Abl immunoprecipitation.
4022 FORAY ET AL. MOL. CELL. BIOL.
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FIG. 2. Localization of the domains involved in the BRCA1–c-Abl complex. (A) Positions of the GST-BRCA1 fusion proteins. (B) Equal amounts
(10 g) of GST fusion proteins (except for GST controls [15 g]) were analyzed by Coomassie blue-stained gels (top) and incubated with 293 cell nuclear
extracts, and the resulting GST adsorbates were subjected to immunoblotting (IB) using anti-c-Abl (c-Abl; Ab-3) antibody (bottom). The GST-
BRCA1#3 protein was found to be unstable, as shown previously (34). (C) Positions of the GST–c-Abl fusion proteins. (D) Equal amounts (5 g) of
GST fusion proteins shown by Coomassie blue-stained gels (top) were incubated with 293 cell nuclear extracts, and the resulting GST adsorbates were
subjected to immunoblotting using anti-BRCA1 (BRCA1; MS110) antibody. (E) Equal amounts (5 g) of GST fusion proteins shown by Coomassie
blue-stained gels (top; the second lane is empty) were incubated with 293 cell nuclear extracts, and the resulting GST adsorbates were subjected to
immunoblotting using anti-c-Abl (Ab-3) antibody (bottom). (F) Eluted wild-type and mutated GST-BRCA1#6 (P1856G and P1859G) proteins were
mixed with eluted GST-SH3 proteins and subjected to BRCA1 immunoprecipitation using anti-BRCA1 (Ab-5 and Ab-3) antibodies. The presence of
the GST-SH3 proteins in the adsorbates was examined by immunoblotting using anti-GST (GST) antibody.
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they are not observed following treatment with -phosphatase
(Fig. 3A). These findings are consistent with previous obser-
vations that BRCA1 undergoes phosphorylation at multiple
sites following exposure to IR (17, 18).
We next examined coimmunoprecipitation of BRCA1 and
c-Abl in the nuclear extracts of irradiated 293 cells (Fig. 3B).
While the BRCA1–c-Abl complex was observed constitu-
tively in unirradiated 293 cells (Fig. 1B) and in 293 cells
collected immediately after irradiation on ice (Fig. 3B), the
amount of c-Abl in immunoprecipitated BRCA1 and the
amount of BRCA1 in the c-Abl immunoprecipitated mate-
rial decreased from 2 to 8 h after irradiation (20 Gy), indi-
cating that disruption of the BRCA1–c-Abl complex occurs
postirradiation (Fig. 3B). This disruption is transient, since
reassociation of BRCA1 and c-Abl was observed 12 h po-
stirradiation (Fig. 3B). Our findings demonstrate that the
FIG. 3. Disruption of the BRCA1–c-Abl complex after irradiation. Control and irradiated (20 Gy) 293 cells were collected at the indicated
times. (A) Nuclear extracts were subjected to BRCA1 and c-Abl immunoblotting (IB) with MS110 and Ab-3 antibodies, respectively. -PPase,
-phosphatase. (B) The same batch of extracts was subjected to BRCA1 and c-Abl immunoprecipitation (IP) with MS110 and Ab-3 antibodies,
respectively. Preimmune mouse IgGs were used as controls. c-Abl, anti-c-Abl; BRCA1, anti-BRCA1. (C) As described in the legend to Fig. 2,
purified GST-BRCA1#6, GST-SH3SH2kinase, GST-SH3, and GST fusion proteins were incubated with nuclear extracts from irradiated 293
cells; GST adsorbates were collected and subjected to BRCA1 or c-Abl immunoblotting using the same antibodies used for Fig. 2.
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BRCA1–c-Abl complex is transiently disrupted after treat-
ment with 20 Gy of IR.
To investigate further the disruption of the BRCA1–c-Abl
complex, pull-down assays were performed by incubating either
the GST-BRCA1#6, GST-SH3, or GST-SH3SH2kinase fu-
sion protein with extracts from unirradiated and irradiated 293
cells. The interaction of c-Abl with GST-BRCA1#6 was greater
in unirradiated cells than in irradiated cells, suggesting a lower
affinity of purified C-terminal BRCA1 for c-Abl activated by IR
(Fig. 3C). In parallel, the amount of BRCA1 protein bound to
GST-SH3SH2kinase and GST-SH3 adsorbates was greater in
unirradiated cells than in irradiated cells subjected to 4 h of
incubation (Fig. 3C).
Finally, to examine whether the BRCA1–c-Abl association is
DNA dependent, immunoprecipitations were performed with
DNase I-pretreated extracts in the presence of ethidium bro-
mide. DNase I treatment had no effect on the association
between BRCA1 and c-Abl, suggesting that formation of the
BRCA1–c-Abl complex is not mediated by DNA (data not
shown).
The radiation-induced disruption of the BRCA1–c-Abl com-
plex is ATM dependent. The phosphorylation of BRCA1 and
the activation of c-Abl kinase is impaired in ATM/ cells (4,
12). We therefore investigated BRCA1–c-Abl association and
disruption in the ATM/ AT5BIVA and control MRC5VI
simian virus 40-transformed human fibroblast cell lines.
BRCA1 phosphorylation was clearly evident in MRC5VI cells
following irradiation, although the kinetics were slightly differ-
ent from those seen in 293 cells (Fig. 3A versus 4A). As
anticipated, no phosphorylation of BRCA1 was seen in
AT5BIVA fibroblasts following exposure to 20 Gy (Fig. 4A),
consistent with previous findings (12, 17). Unlike MRC5VI
cells, the radiation-induced disruption of the BRCA1–c-Abl
complex was not observed in ATM/ cells, raising the possi-
bility that radiation-induced phosphorylation of BRCA1
and/or the activation of c-Abl, which is ATM dependent, is
required to disrupt the BRCA1–c-Abl complex (Fig. 4B).
To investigate further the disruption of the BRCA1–c-Abl
complex in ATM/ cells, pull-down assays were performed by
incubating either GST-BRCA1#6, GST-SH3, or GST-SH3
FIG. 4. Disruption of the BRCA1–c-Abl complex is ATM dependent. Control and irradiated (20 Gy) MRC5VI and AT5BIVA fibroblast cells
were collected at the indicated times. (A) Nuclear extracts were subjected to BRCA1 and c-Abl immunoblotting (IB) with MS110 and Ab-3
antibodies, respectively. c-Abl, anti-c-Abl; BRCA1, anti-BRCA1. (B) The same batch of extracts was subjected to BRCA1 and c-Abl
immunoprecipitation (IP) with the same antibodies and preimmune IgGs used for Fig. 3. (C) Equal amounts (10 g) of purified GST and
GST-BRCA1#6 fusion proteins (see the Coomassie blue-stained gel in Fig. 2) were incubated with nuclear extracts from irradiated AT5BIVA cells
subjected or not to 4 h of incubation. The resulting GST adsorbates were analyzed by immunoblotting using the anti-c-Abl (Ab-3) antibody. Equal
amounts (5 g) of purified GST, GST-SH3SH2kinase, and GST-SH3 fusion protein (see the Coomassie blue-stained gel in Fig. 2) were
incubated with nuclear extracts from irradiated AT5BIVA cells subjected or not to 4 h of incubation. The resulting adsorbates were analyzed by
immunoblotting with the anti-BRCA1 (MS110) antibody.
VOL. 22, 2002 BRCA1–c-Abl ASSOCIATION 4025
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SH2kinase fusion protein with extracts from unirradiated and
irradiated ATM/ cells. Using the same fusion protein prepara-
tions used with 293 cells (Fig. 2 and 3C), GST-BRCA1#6 inter-
acted with endogenous c-Abl from ATM/ cells independently
of whether the cells were irradiated (Fig. 4C). Similarly, using the
GST-SH3SH2kinase and GST-SH3 fusion proteins, the inter-
action with BRCA1 from ATM/ cells was maintained following
irradiation (Fig. 4C).
We also observed a constitutive BRCA1–c-Abl complex and
its radiation-induced disruption in HeLa and MCF7 (BRCA1-
and c-Abl-positive) cells and in MO59J (DNA-PKcs/) and
SaOS2 (Rb/) tumor cells (data not shown). Moreover, in
BRCA2/ Capan1 tumor cells, the amount of BRCA1–c-Abl
complex is considerably reduced, and its radiation-induced dis-
ruption occurs earlier than 4 h, raising the possibility that
BRCA2 may also participate in the BRCA1–c-Abl association
(data not shown).
The radiation-induced disruption of BRCA1–c-Abl complex
correlates temporally with the increase of c-Abl tyrosine ki-
nase activity. To quantify the endogenous c-Abl tyrosine ki-
nase activity, we immunoprecipitated c-Abl and carried out a
kinase assay using a c-Abl autophosphorylation peptide as a
substrate (23). Following irradiation, the c-Abl tyrosine kinase
activity of 293 cells increased slightly at 1 h, reached a maxi-
mum at 4 h, and then decreased after 8 h, declining up to 12 h
(Fig. 5A). This correlates temporally with the phosphorylation
of BRCA1 observed by immunoblotting and the disruption of
the complex (Fig. 3A and B).
FIG. 5. Tyrosine kinase activity of c-Abl after irradiation. (A) Tyrosine kinase activity of c-Abl measured from c-Abl immunoprecipitates (IP)
of nuclear extracts from 293 cells exposed to 20 Gy and collected after irradiation at the indicated times. (B) Tyrosine kinase activity of c-Abl in
nuclear extracts from 293, MRC5VI, AT5BIVA (ATM/), and HCC1937 (BRCA1-mutated) cells exposed to 20 Gy and incubated for the times
indicated. HCC1937 cells were infected by empty cassette (Adco1), wild-type BRCA1 (AdBRCA1) adenoviruses, or adenoviruses expressing only
the first 1,321 residues of BRCA1 (Ad1025). All the data presented are the mean plus standard error of triplicate experiments. The assay was
controlled, with each sample using an anti-c-Abl (Ab-1) antibody that inhibits kinase activity, as recommended by the manufacturers (see Materials
and Methods). We verified that the levels of c-Abl protein immunoprecipitated in all samples were similar (data not shown). (C) As a control for
adenovirus expression, nuclear extracts from exponentially growing adenovirus-infected HCC1937 cells were subjected to immunoblotting (IB)
using anti-BRCA1 (BRCA1; MS110) and anti-c-Abl (c-Abl; Ab-3) antibodies. It is noteworthy that the Ad1025 adenovirus produces a 156-kDa
truncated BRCA1 protein.
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BRCA1-mutated cells show constitutively elevated c-Abl ac-
tivity. If the radiation-induced activation of c-Abl is causally
related to the disruption of the BRCA1–c-Abl complex, a
prediction is that cells with impaired BRCA1 function should
have constitutively high c-Abl tyrosine kinase activity. We
therefore examined c-Abl activity in unirradiated and irradi-
ated 293 (BRCA1-positive), HCC1937 (BRCA1-mutated),
AT5BIVA (ATM/), and control MRC5VI cell extracts. The
c-Abl kinase activity measured in ATM/ cells was low and
did not increase significantly following radiation treatment, in
agreement with previous reports (Fig. 5B) (4). Significantly, we
observed elevated tyrosine kinase activity in HCC1937 cells
and no further elevation postirradiation (Fig. 5B).
To verify that this is due to lack of BRCA1 function,
HCC1937 cells were infected with adenovirus containing wild-
type or mutant BRCA1. In the cells infected with wild-type
BRCA1, the spontaneous c-Abl tyrosine kinase activity was
decreased, although the activity did not return to the level seen
in control cells (Fig. 5B). Although HCC1937 cells are effi-
ciently infected, we have only observed partial correction in all
parameters monitored, including cellular radiosensitivity and
double-strand break repair (data not shown). As controls, no
change in tyrosine kinase activity was observed following in-
fection with an empty cassette or with a mutant Ad1025 ade-
novirus expressing only the first 1,321 residues of BRCA1 (Fig.
5B). Immunoblotting was carried out to verify expression of
BRCA1 in infected cells. The adenovirus infection did not
significantly affect the expression of c-Abl (Fig. 5C). Together,
these data suggest that BRCA1 expression serves to prevent
c-Abl acting as a tyrosine kinase.
The C-terminal domain of BRCA1 is a substrate for c-Abl
tyrosine kinase. It has been reported previously that BRCA1 is
modified at tyrosine residues (32, 43, 51). The association of
c-Abl with BRCA1 raises the possibility that c-Abl might mod-
ify BRCA1 and that this modification might influence the in-
teraction. We, therefore examined whether an SH2 kinase
fragment of c-Abl that is sufficient for tyrosine kinase activity
(23) is able to phosphorylate the GST-BRCA1#6 fusion pro-
tein. A GST-CTD fusion fragment was used as a control sub-
strate. Although the phosphorylation of GST-CTD is stronger,
c-Abl efficiently phosphorylated GST-BRCA1#6, suggesting
that the C terminus of BRCA1 is an in vitro substrate for the
c-Abl kinase activity (Fig. 6A). No significant phosphorylation
has been observed for the other GST-BRCA1 fusion proteins
used in this study (data not shown). As a first step to investigate
whether this modification might cause the disruption of the
complex, we also examined whether the tyrosine-phosphory-
lated GST-BRCA1#6 could interact with GST-SH3. No effect
on the interaction was observed (Fig. 6B).
The phosphorylation reaction described above utilizes a
truncated form of c-Abl. We also examined the ability of en-
dogenous c-Abl to phosphorylate the BRCA1 protein by car-
rying out a c-Abl kinase assay using GST-BRCA1#6 as a
substrate and immunoprecipitated c-Abl derived from unirra-
diated or irradiated MRC5VI (controls) and AT5BIVA
(ATM/) fibroblasts as the source of c-Abl (Fig. 6C). Only the
c-Abl obtained from irradiated MRC5VI cells was able to
phosphorylate GST-BRCA1#6; no significant phosphorylation
was observed with unirradiated controls or with either irradi-
ated or unirradiated AT5BIVA cells (Fig. 6C). Thus, c-Abl
kinase activated endogenously can also phosphorylate the C
terminus of BRCA1. To investigate further the possibility that
BRCA1 is phosphorylated by c-Abl tyrosine kinase in vivo, we
rehybridized the same membrane used in Fig. 3A with phos-
photyrosine-specific antibodies. We observed no constitutive
tyrosine phosphorylation of BRCA1 but clear radiation-in-
duced phosphorylation (Fig. 6D, top). Moreover, no tyrosine-
phosphorylated BRCA1 was observed in AT5BIVA fibroblasts
whether irradiated or not (Fig. 6D, bottom). This result shows
that BRCA1 is phosphorylated at tyrosine residues in a radi-
ation- and ATM-dependent manner. Since this correlates with
the activation of c-Abl, it strongly implicates c-Abl as the
responsible kinase.
Radiation-induced disruption of the BRCA1–c-Abl complex
is not dependent upon c-Abl activation. Two phosphorylation
events involving BRCA1 may underlie the radiation-induced
disruption of the BRCA1–c-Abl complex: ATM-dependent
phosphorylation (at serine and threonine residues) or c-Abl-
dependent tyrosine phosphorylation that we demonstrated also
occurs (see above). The observation that the disruption is not
observed in ATM/ cells is not informative in this context,
since neither ATM-dependent BRCA1 phosphorylation nor
c-Abl activation occurs in ATM/ cells. Our findings de-
scribed above suggest that tyrosine phosphorylation of GST-
BRCA1#6 does not affect interaction with the GST-SH3 con-
struct. To address further the role of c-Abl phosphorylation of
BRCA1 in the radiation-induced disruption of the BRCA1–c-
Abl complex, we exploited the EA to inhibit c-Abl tyrosine
kinase activity in 293 cells. EA treatment resulted in a three-
fold decrease in c-Abl kinase activity 4 h postirradiation and
prevented the radiation-induced tyrosine phosphorylation of
BRCA1 (Fig. 7A and B). (It is noteworthy that both in the
absence and presence of EA, the majority of BRCA1 migrates
with a slower mobility postirradiation. However, a small frac-
tion that maintains the mobility of BRCA1 seen in unirradi-
ated cells is visible when analyzed using low-percentage poly-
acrylamide gels (Fig. 3A). We attribute the mobility shift to
multiple ATM-dependent serine and threonine phosphoryla-
tion events. The tyrosine-phosphorylated form of BRCA1
identified using the phosphotyrosine-specific antibodies has
the mobility of BRCA1 seen in unirradiated cells, suggesting
that this represents a distinct, minor fraction of BRCA1 (see
Discussion). We next investigated whether EA inhibition of
BRCA1 tyrosine phosphorylation affects the radiation-induced
disruption of the BRCA1–cAbl complex by examining the
presence of c-Abl or BRCA1 in immunoprecipitated BRCA1
or c-Abl material as shown in Fig. 3B. The amount of c-Abl in
immunoprecipitated BRCA1 and the amount of BRCA1 in the
immunoprecipitated c-Abl material decreased 4 h postirradia-
tion (20 Gy) in the EA-treated cells as efficiently as that seen
in cells not exposed to EA (Fig. 7C versus 3B). Hence, we
conclude that neither c-Abl activation nor tyrosine phosphor-
ylation of BRCA1 is required for the radiation-induced dis-
ruption of the BRCA1–c-Abl complex.
DISCUSSION
Multiprotein repair complexes. BRCA1 appears to be a
central component of a large multiprotein complex with bind-
ing demonstrated to BRCA2, RAD51 (10, 34), ATM (12),
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ATR (38), RAD50-MRE11-NBS (52), and a BASC protein
component (45). Additionally, the redistribution of BRCA1 in
complexes appears to change following replication blockage
(11). However, while there is increasing evidence that such
complexes are essential for genome surveillance, the biological
role and dynamic release of each participant remains to be
investigated. Here, a BRCA1–c-Abl complex is identified. Fol-
lowing irradiation and incubation, the BRCA1–c-Abl complex
was disrupted in an ATM-dependent manner, which occurred
concomitantly with an ATM-dependent increase of c-Abl ty-
rosine kinase activity and an ATM-dependent phosphorylation
of BRCA1.
Specificity of the BRCA1–c-Abl interaction. The BRCA1–c-
Abl interaction has been shown to be mediated by the C
terminus of BRCA1 and the N terminus of c-Abl. The C-
terminal domain of BRCA1 is suggested to function in trans-
activation and mediates DNA and protein interactions via the
BRCT motifs (20, 47). However, the interaction of c-Abl with
the BRCT domain alone appears to be weaker than that ob-
served with a longer C-terminal fragment of BRCA1. Addi-
FIG. 6. C-terminal BRCA1 is a substrate for c-Abl tyrosine kinase. (A) c-Abl tyrosine kinase assay of GST-BRCA1#6 using c-Abl SH2 kinase.
Purified c-Abl SH2 kinase (1 g) was incubated with equal amounts (5 g) of GST, GST-CTD, and GST-BRCA1#6 fusion proteins as indicated
in Materials and Methods (top). The resulting GST adsorbates were subjected to SDS-PAGE and phosphorimager analysis (bottom). (B) SH3
binding of c-Abl-phosphorylated GST-BRCA1#6 substrates. Equal amounts of GST-BRCA1#6, whether tyrosine phosphorylated (#6*) or not
(#6) as described below, were subjected to BRCA1 immunoprecipitation (IP) using anti-BRCA1 (BRCA1; Ab-5 and Ab-3) antibodies. The
substrates were mixed with equal amounts of eluted GST-SH3 proteins. The presence of the GST-SH3 proteins in the adsorbates was examined
by immunoblotting (IB) using anti-GST (GST) antibody. (C) c-Abl tyrosine kinase assay of GST-BRCA1#6 using endogenous c-Abl. c-Abl
immunoprecipitates of nuclear extracts from MRC5VI and AT5BIVA (ATM/) cells exposed to 20 Gy were collected after irradiation at the
indicated times (top) in a kinase assay with the GST-BRCA1#6 fusion protein (5 g) as a substrate. The resulting GST adsorbates were subjected
to SDS-PAGE and phosphorimager analysis (bottom). (D) The nitrocellulose membrane used for BRCA1 immunoblotting of 293 cells extracts
shown in Fig. 3A was rehybridized by anti-p-Tyr ( p Tyr) tyrosine antibody (top). Nuclear extracts from unirradiated and irradiated MRC5VI and
AT5BIVA cells were subjected to p-Tyr immunoblotting (bottom).
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tionally, c-Abl does not interact with the second BRCT domain
alone (data not shown). We therefore conclude that the BRCT
domains alone are insufficient for optimal c-Abl binding (see
below). Following irradiation, c-Abl undergoes ATM-depen-
dent modification such that it is no longer able to bind the
C-terminal fragment of BRCA1. We also observed a constitu-
tive interaction between endogenous BRCA1 and the SH3
domain of c-Abl that disappears postirradiation. Thus, the
binding of BRCA1 to the SH3 domain of c-Abl correlates with
the in vivo interaction between BRCA1 and c-Abl, suggesting
that this domain is the mediator of complex formation with
BRCA1. The SH3 domain of c-Abl has a high affinity for
proline-rich PXXP sites (36), and notably, there is such a motif
at residue 1853 in the C terminus of BRCA1 which lies outside
the BRCT domain but is present in GST-BRCA1#6. Mutation
of either of the two prolines prevents the SH3-BRCA1 inter-
action (Fig. 2E and F). Taken together, our findings provide
evidence for a direct interaction between the PXXP site of
BRCA1 and the SH3 domain of c-Abl.
We have shown that c-Abl can phosphorylate the C-terminal
domain of BRCA1 in vitro, and we provide evidence that
BRCA1 is an in vivo c-Abl substrate, since BRCA1 is tyrosine
phosphorylated after radiation treatment in an ATM-depen-
dent manner, which correlates temporally with c-Abl activa-
tion. Furthermore, treatment with EA, a specific c-Abl inhib-
itor (41), prevents this phosphorylation. It is noteworthy that,
whereas the major proportion of BRCA1 undergoes a marked
mobility shift postirradiation, most likely due to multiple serine
FIG. 7. Effect of c-Abl kinase inhibition on the BRCA1–c-Abl complex. (A) c-Abl tyrosine kinase activity measured following c-Abl immu-
noprecipitation of nuclear extracts from untreated and EA-treated 293 cells exposed to 20 Gy and collected at the indicated times postirradiation.
The error bars indicate standard deviations. (B) Nuclear extracts from irradiated control or EA-treated 293 cells were subjected to p-Tyr and
BRCA1 immunoblotting (IB).  p Tyr, anti-p-Tyr; BRCA1, anti-BRCA1. (C) Nuclear extracts from control and EA-treated cells were subjected
to BRCA1 and c-Abl immunoprecipitation (IP) for BRCA1–c-Abl interaction using MS110 and Ab-3 antibodies, respectively. Preimmune mouse
IgGs were used as controls. c-Abl, anti-c-Abl. The experiments shown in panels B and C were carried out using 4% polyacrylamide gels in contrast
to the experiment shown in Fig. 3A, where higher-percentage polyacrylamide gels were used. The difference in mobility shift postirradiation is
therefore less pronounced in panels B and C.
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and threonine phosphorylation events (Fig. 3A), the phospho-
tyrosine-modified BRCA1 retains the mobility of BRCA1
present in unirradiated cells. This is consistent with a previous
report that BRCA1 tyrosine modifications are less common
than serine and threonine phosphorylations and suggests ad-
ditionally that only a minor fraction of BRCA1 undergoes
tyrosine phosphorylation and that this represents a fraction
distinct from that receiving serine and threonine phosphoryla-
tion (32).
Radiation-induced disruption of the BRCA1–c-Abl complex.
At 4 h following irradiation with 20 Gy, a number of events
have taken place in 293 cells: BRCA1 is phosphorylated, the
tyrosine activity of c-Abl is activated, and the BRCA1–c-Abl
complex is disrupted. None of these events are detected in
ATM/ cells. Our binding studies with the GST fusion pro-
teins suggests that ATM-dependent, radiation-induced modi-
fications to both BRCA1 and c-Abl influence the BRCA1–c-
Abl interaction. Previous studies have shown that ATM
phosphorylates serine residues of BRCA1 in response to DNA
damage (12) and that ATM influences the activation of c-Abl
tyrosine kinase after irradiation (4). Our results raise the ques-
tion whether BRCA1–c-Abl dissociation precedes and causes
c-Abl activation or, conversely, c-Abl tyrosine kinase activation
causes BRCA1–c-Abl disruption, possibly by tyrosine phos-
phorylation of BRCA1. In this context, three key observations
suggesting that c-Abl activation is a consequence of the dis-
ruption of the complex rather than inducing the disruption are
as follows. (i) Cells lacking BRCA1 have constitutively elevated
c-Abl tyrosine kinase activity. Assuming that c-Abl is not con-
stitutively phosphorylated in BRCA1-mutated cells, this shows
that c-Abl activation arises as a consequence of the lack of a
BRCA1–c-Abl complex. (ii) Abrogation of c-Abl tyrosine ki-
nase activity by EA does not impact upon BRCA1–c-Abl dis-
ruption. (iii) Tyrosine phosphorylation of GST-BRCA1#6 did
not affect its interaction with GST-SH3. The observation that
only a minor subset of BRCA1 undergoes phosphotyrosine
modification further supports this notion.
We therefore propose a model in which BRCA1 together
with ATM functions to control the tyrosine kinase activity of
c-Abl (Fig. 8). In unirradiated cells, BRCA1 and c-Abl are
associated in a complex which acts to suppress c-Abl tyrosine
kinase activity. Following irradiation, both BRCA1 and c-Abl
are phosphorylated at serine residues directly or indirectly by
ATM. One or both of these events drives the disruption of the
BRCA1–c-Abl complex, which results in activation of c-Abl
tyrosine kinase activity. This activity then modifies BRCA1 at
tyrosine residues, but this may represent only a minor fraction
of BRCA1; its functional significance is unclear, but it is not a
driving force in disrupting the BRCA1–c-Abl complex (Fig. 8).
In addition to the radiation-induced activation of c-Abl,
c-Abl activity is also activated in S phase. In S phase, Rb is
hyperphosphorylated and dissociates from c-Abl (46). BRCA1
has been shown to interact physically with the A-B pocket site
of Rb and to release Rb in S phase (1, 42). Our findings raise
the possibility that a BRCA1–Rb–c-Abl complex participates
in cell cycle regulation and is also disrupted following irradia-
tion. Other multiprotein complexes involving BRCA1 protein
have been shown to be disrupted after irradiation. For exam-
ple, BRCA1 and hCds/Chk2 and BRCA1 and CtIP interact
constitutively and dissociate after irradiation in an ATM-de-
pendent manner (26, 27). Together, these findings suggest that
BRCA1 and ATM may act to coordinate the regulation of cell
cycle control, DNA repair, and apoptosis via the regulation of
protein complexes.
Biological function of the BRCA1–c-Abl complex and its
disruption. Our findings show that BRCA1 contributes to the
regulation of c-Abl activity. Activation of c-Abl has been re-
ported to have several distinct and potentially disparate effects.
First, it has been linked to the onset of apoptosis via the
JNK/SAPK pathways (19, 24, 36). Conversely, and probably by
a distinct mechanism, activation of c-Abl, for example, in BCR/
ABL translocations, results in elevated tumor incidence (13).
Additionally, previous observations have linked c-Abl to both
of the double-strand break repair pathways, homologous re-
combination and nonhomologous end joining. On the one
hand, c-Abl has been reported to inhibit in vitro the DNA
strand exchange properties mediated by RAD51 and to con-
tribute to the disruption of the DNA-protein kinase complex
(21, 49). More recently, however, it has been reported that
activation of c-Abl upregulates RAD51 expression and homol-
FIG. 8. Model for the association and disruption of the BRCA1–c-Abl complex and its role. BRCA1 and c-Abl interact constitutively, and c-Abl
tyrosine kinase activity is inhibited. After irradiation, ATM kinase is activated, phosphorylating BRCA1 and activating c-Abl, causing disruption
of the complex. Consequently, the c-Abl tyrosine kinase activity is stimulated, leading to phosphorylation of a minor subset of BRCA1.
4030 FORAY ET AL. MOL. CELL. BIOL.
 o
n
 June 19, 2014 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
ogous recombination activity (37). Either effect could influence
the nature and/or fidelity of DNA repair and thereby influence
the response to DNA damage. Which of these disparate events
takes place may depend upon the tissue or the level of acti-
vated c-Abl.
In conclusion, our findings demonstrate that BRCA1 and
c-Abl coassociate constitutively and that exposure to IR trig-
gers an ATM-dependent disruption of this BRCA1–c-Abl
complex, which coincides with the activation of c-Abl kinase
activity. Loss of BRCA1 results in constitutively elevated c-Abl
kinase activity, suggesting that BRCA1 is involved in the con-
trol of c-Abl kinase activity. This suggests a route by which
BRCA1 impacts upon cellular responses to DNA damage dis-
tinct from a direct role in DNA repair or a role in cell cycle
checkpoint control.
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